Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Conditions
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Trial Timeline
Nov 28, 2016 → Nov 27, 2023
NCT ID
NCT02937818About Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparib
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparib is a phase 2 stage product being developed by AstraZeneca for Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02937818. Target conditions include Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02937818 | Phase 2 | Completed |
Competing Products
20 competing products in Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma